Metabolic Syndrome, Alzheimer Disease, Schizophrenia, and Depression: Role for Leptin, Melatonin, Kynurenine Pathways, and Neuropeptides

Metabolic Syndrome and Neurological Disorders

Volumn , Issue , 2013, Pages 235-248

  Anderson, George ^a   Maes, Michael ^b  

^a CRC   (United Kingdom)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Alzheimer disease; Depression; Kynurenine pathways; Leptin; Melatonin; Metabolic dysregulation; Neuropeptides; Schizophrenia

Indexed keywords

EID: 85014121879     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118395318.ch13     Document Type: Chapter

References (116)

1. Menon RR, Barta PE, Aylward EH, Richards SS, Vaughn DD, Tien AY, et al. Posterior superior temporal gyrus in schizophrenia: grey matter changes and clinical correlates. Schizophr Res. 1995; 162:127-135.
2. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci BiobehavRev. 2011;35:804-817.
3. Jungerius BJ, Hoogendoorn ML, Bakker SC, Van'tSlot R, Bardoel AF, Ophoff RA, et al. An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. Mol Psychiatr. 2008;13:1060-1068.
4. Akanji AO, Ohaeri JU, Al-Shammri SN, Fatania HR. Apolipoprotein E polymorphism and clinical disease phenotypes in Arab patients with schizophrenia. Neuropsychobio. 2009;60:67-72.
5. Liu J, Liu J, Zhou Y, Li S, Li Y, Song X, et al. Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA Cell Biol. 2011;30:913-917.
6. Zaharieva I, Georgieva L, Nikolov I, Kirov G, Owen MJ, O'Donovan MC, et al. Association study in the 5q31-32 linkage region for schizophrenia using pooled DNA genotyping. BMC Psychiatr. 2008;8:11.
7. Bradshaw NJ, Porteous DJ. DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacol. 2012;62:1230-1241.
8. Zhang J, Chen J, Xu Q, Shen Y. Does the presenilin 2 gene predispose to schizophrenia? Schizophr Res. 2009;109(1-3):121-129.
9. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatr. 2010;167: 261-280.
10. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflamm. 2012;9:151.
11. Gozdzik-Zelazny A, Borecki L, Pokorski M. Depressive symptoms in schizophrenic patients. Eur J Med Res. 2011;16:549-552.
12. Gorwood P, Corruble E, Falissard B, Goodwin GM. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatr. 2008;165: 731-739.
13. Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatr. 2013;42:101-114.
14. Businaro R, Ippoliti F, Ricci S, Canitano N, Fuso A. Alzheimer's disease promotion by obesity: induced mechanisms-molecular links and perspectives. Curr Gerontol Geriatr Res 2012;2012:986823.
15. Cai H, Cong WN, Ji S, Rothman S, Maudsley S, Martin B. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res. 2012;9:5-17.
16. Kendell RE, Juszczak E, Cole SK. Obstetric complications and schizophrenia: a case control study based on standardised obstetric records. Br J Psychiatr. 1996;168:55-61.
17. Anderson G, Maes M. Schizophrenia: Linking prenatal infection to hypoNMDAr, Immune-inflammation, demyelination, susceptibility genes, IDO, neuroprogression and treatment. Prog Neuropsychopharmacol Biol Psychiatr. 2013;42:5-19.
18. Luchowska E, Kloc R, Olajossy B, Wnuk S, Wielosz M, Owe-Larsson B, et al. beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling. Prog Neuropsychopharmacol Biol Psychiatr.2009;33:519-529.
19. Ohira K, Hagihara H, Toyama K, Takao K, Kanai M, Funakoshi H, et al. Expression of tryptophan 2,3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Br. 2010;3:26.
20. Pan W, Hsuchou H, Jayaram B, Khan RS, Huang EY, Wu X, et al. Leptin actiuon on non-neuronal cells in the CNS: potential clinical applications. Ann N Y Acad Sci. 2012;1264:64-71.
21. Lam QL,Wang S, Ko OK, Kincade PW, Lu L. Leptin signalling maintains B-cell homeostasis via induction of Bcl-2 and Cyclin D1. Proc Natl Acad Sci U S A. 2010;107:13812-13817.
22. Silva R, Mesquita AR, Bessa J, Sousa JC, Sotiropoulos I, Lẽao P, et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neurosci. 2008;152:656-669.
23. Beccano-Kelly D, Harvey J. Leptin: a novel therapeutic target in Alzheimer's disease? Int J Alzheimers Dis. 2012;2012:594137.
24. Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci. 2012;69:741-762.
25. Marrero MB, Lucas R, Salet C, Hauser TA, Mazurov A, Lippiello PM, et al. An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J Pharmacol Exp Ther. 2010;332:173-180.
26. Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci. 2010;55:204-211.
27. Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M. AMP-activated protein kinase: a potential player in Alzheimer's disease. JNeurochem. 2011;118:460-474.
28. Valles SL, Dolz-Gaiton P, Gambini J, Borras C, Lloret A, Pallardo FV,et al. Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes. Br Res. 2010;1312:138-144.
29. Greco SJ, Hamzelou A, Johnston JM, Smith MA, Ashford JW, Tezapsidis N. Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and ±-amyloid in neurons. BBRC. 2011;414:170-174.
30. Lynch CJ, Shah ZH, Allison SJ, Ahmed SU, Ford J, Warnock LJ, et al.SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53. PLoS One. 2010;5:e13502.
31. Grant R, Nguyen S. and Guillemin G. Kynurenine pathway Metabolism is Involved in the Maintenance of the Intracellular NAD+ concentration in Human primary Astrocytes. Int.J.Tryptoph Res. 2010;3: 151-156.
32. Garćia-Ćaceres C, Fuente-Martin E, Burgos-Ramos E, Granado M, Frago LM, Barrios V, et al. Differential acute and chronic effects of leptin on hypothalamic astrocyte morphology and synaptic protein levels. Endocrinol. 2011;152(5):1809-1818.
33. Banks WA. Role of the blood-brain barrier in the evolution of feeding and cognition. Ann N Y Acad Sci. 2012;1264(1):13-19.
34. Dietrich MO, Spuch C, Antequera D, Rodal I, de Ýebenes JG, Molina JA, et al. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging. 2008;29:902-912.
35. Fukuda M, Williams KW, Gautron L, Elmquist JK. Induction of leptin resistance by activation of cAMP-Epac signaling. Cell Metab. 2011;13:331-339.
36. Kuo PH, Kao CF, Chen PY, Chen CH, Tsai YS, Lu ML, et al. Polymorphisms of INSIG2, MC4R, and LEP are associated with obesity-and metabolicrelated traits in schizophrenic patients. J Clin Psychopharmacol. 2011;31:705-711.
37. Heckers S. Diagnostic criteria for schizoaffective disorder. Expert Rev Neurother. 2012;12:1-3.
38. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR. Peripheral and cerebral metabolic abnormalities of the tryptophankynurenine pathway in a murine model of major depression. Behav Br Res. 2010;210:84-91.
39. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety-and depression-like behaviours in mice: focus on individual differences. Pharmacol Biochem Behav. 2011:98:161-168.
40. Anderson G, Ojalla J. Alzheimer's and Seizures: Interleukin-18, Indoleamine 2,3-Dioxygenase and Quinolinic Acid. Int.J.Tryptoph Res. 2010;3:169-173.
41. Pistell PJ, Morrison CD, Gupta S, Knight AG, Keller JN, Ingram DK, Bruce-Keller AJ. Cognitive impairment following high fat diet consumption is associated with brain inflammation. J Neuroimmunol. 2010;219:25-32.
42. Keller L, Xu W,Wang HX,Winblad B, Fratiglioni L, Graff C. The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer's disease risk: A prospective cohort study. J Alzheimers Dis 2011;23:461-469.
43. Businaro R, Ippoliti F, Ricci S, Canitano N, Fuso A. Alzheimer's disease promotion by obesity: induced mechanisms-molecular links and perspectives. Curr Gerontol Res. 2012;2012:986823.
44. Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009;302:2565-2572.
45. Benzler J, Ganjam GK, Kruger M, Pinkenburg O, Kutschke M, Stohr S, et al. Hypothalamic glycogensynthase-kinase 3± has a central role in the regulation of food intake and glucose metabolism. Biochem J. 2012;447(1):175-184.
46. Marwarha G, Dasari B, Prasanthi JR, Schommer J, Ghribi O. Leptin reduces the accumulation of Abeta and phosporylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis. 2010;19:1007-1019.
47. Feng J, Zhang P, Chen X, He G. PI3K and ERK/Nrf2 pathways are involved in oleanolic acid-indeced heme oxygenase-1 expression in rat vascular smooth muscle cells. J Cell Biochem. 2011;112:1524-1531.
48. Thomas SR, Stocker R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep.1999;4:199-220.
49. Gupta BB, Yanthan L, Singh KM. In vitro effects of 5-hydroxytryptophan, indoleamines and leptin on arylalkylamine N-acetyltransferase (AA-NAT) activity in pineal organ of the fish, Clarias gariepinus (Burchell, 1822) during different phases of the breeding cycle. Indian J Exp Biol. 2010;48:786-792.
50. Couto-Moraes R, Palermo-Neto J, Markus RP. The immune-pineal axis: stress as a modulator of pineal gland function. Ann N Y Acad Sci. 2009;1153:193-202.
51. Cardinali DP, Esquifino AI, Srinivasan V, Pandi-Perumal SR. Melatonin and the immune system in aing. Neuroimmunomod. 2008;15:272-278.
52. Agil A, Navarro-Alarcon M, Ruiz R, Abuhamadah S, El-Mir M-Y, Vazquez GF. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J. Pineal Res. 2011;50:207-212.
53. Martin M, Maćias M, Léon J, Escames G, Khaldy H, Acuña-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production ofATP in rat brain and liver mitochondria. Int J Biochem Cell Biol. 2002;34:348-357.
54. Zhang L, Su P, Xu C, Chen C, Liang A, Du K, et al. Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPAR expression and enhancing Runx2 expression. J Pineal Res. 2010;49:364-372.
55. Zhou R, Deng J, Zhang M, Zhou HD,Wang YJ. Association between bone mineral density and the risk of Alzheimer's disease. J Alzheimers Dis. 2011;24: 101-108.
56. Chun RF, Gacad M, Nguyen L, Hewison M, Adams JS. Co-chaperone potentiation of vitamin D receptormediated transactivation: a role for Bcl2-associated athanogene-1 as an intracellular-binding protein for 1,25-dihydroxyvitamin D3. J Mol Endocrinol. 2007;39:81-89.
57. Marwarha G, Prasanthi JR, Schommer J, Dasari B, Ghribi O. Molecular interplay between leptin, insulin-like growth factor-1, and ±-amyloid in organotypic slices from rabbit hippocampus. Mol Neurodegener. 2011;6:41.
58. Raḿirez CM, Gonźalez M, Diaz M, Alonso R, Ferrer I, Santpere G, et al.VDAC and ERalpha interaction in caveolae from human cortex is altered in Alzheimer's disease. Mol Cell Neurosci. 2009;42:172-183.
59. Ṕerez-Gonźalez R, Antequera D, Vargas T, Spuch C, Boĺos M, Carro E. Leptin induces proliferation of neuronal progenitors and neuroprotection in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2011;24:17-25.
60. Liu H, Kaur J, Dashtipour K, Kinyamu R, Ribak CE, Friedman LK. Suppression of hippocampal neurogenesis is associated with developmental stage, number of perinatal seizure episodes, and glucocorticosteroid level. Exp Neurol. 2003;184:196-213.
61. Bujalska IJ, Gathercole LL, Tomlinson JW, Darimont C, Ermolieff J, Fanjul AN, et al. A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol. 2008;197:297-307.
62. Herpfer I, Lieb K. Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatr. 2003 Apr,4:56-63.
63. Singewald N, Chicchi GG, Thurner CC, Tsao KL, Spetea M, Schmidhammer H, et al. Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J Neurochem. 2008;106:2476-2488.
64. Renoldi G, Invernizzi RW. Blockade of tachykinin NK1 receptors attenuates stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex. J Neurosci Res. 2006;84:961-968.
65. Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, et al. 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressantinduced desensitization. J Neurosci. 2001;21:8188-8197.
66. Herpfer I, Hunt SP, Stanford SC. A comparison of neurokinin 1 receptor knock-out (NK1-/-) and wildtype mice: exploratory behaviour and extracellular noradrenaline concentration in the cerebral cortex of anaesthetised subjects. Neuropharmacol. 2005;48:706-719.
67. Yan TC, Hunt SP, Stanford SC. Behavioral and neurochemical abnormalities in mice lacking functional tachykinin-1 (NK1) receptors: a model of attention deficit hyperactivity disorder. Neuropharmacol. 2009;57:627-635.
68. Munoz M, Covenas R. NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem. 2011;18:1820-1831.
69. Ebner K, Muigg P, Singewald G, Singewald N. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann N Y Acad Sci. 2008;1144:61-73.
70. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatr Res.10;36:169-175.
71. Ishida T, Uchida H, Suzuki T, Nakajima S,Watanabe K, Kashima H. Plasma substance P level in patients with schizophrenia: a cross-sectional study. Psychiatr Clin Neurosci. 2011;65:526-528.
72. Nagamine T. Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics. Neuropsychiatr Dis Treat 2008;4:289-294.
73. Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest. 2012;122:2454-2468.
74. Yu YJ, Arttamangkul S, Evans CJ, Williams JT, von Zastrow M. Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of mu-opioid receptors in CNS neurons. J Neurosci. 2009;29:222-233.
75. Roche M, Kerr DM, Hunt SP, Kelly JP. Neurokinin-1 receptor deletion modulates behavioural and neurochemical alterations in an animal model of depression. Behav Brain Res. 2012;228:91-98.
76. Sreepathi HK, Ferraguti F. Subpopulations of neurokinin 1 receptor-expressing neurons in the rat lateral amygdala display a differential pattern of innervation from distinct glutamatergic afferents. Neurosci. 2012;203:59-77.
77. Anderson G. Neuronal-Immune Interactions in Mediating Stress Effects in the Etiology and Course of Schizophrenia: Role of the Amygdala in Developmental Co-ordination. Med. Hypoth. 2011;76: 54-60.
78. Yang AR, Yi HS, Mamczarz J, June HL Jr, Hwang BH, June HL Sr. Deficits in substance P mRNA levels in the CeA are inversely associated with alcoholmotivated responding. Synapse. 2009;63:972-981.
79. Kertes E, Ĺaszĺo K, Berta B, Ĺeńard L. Positive reinforcing effects of substance P in the rat central nucleus of amygdala. Behav Brain Res. 2009;205:307-310.
80. Lanoix D, Gúerin P, Vaillancourt C. Placental melatonin production and melatonin receptor expression are altered in preeclampsia: new insights into the role of this hormone in pregnancy. J Pineal Res. 2012;53(4):417-425.
81. Mukda S, Møller M, Ebadi M, Govitrapong P. The modulatory effect of substance P on rat pineal norepinephrine release and melatonin secretion. Neurosci Lett. 2009;461:258-261.
82. Liu YJ, Zhuang J, Zhu HY, Shen YX, Tan ZL, Zhou JN. Cultured rat cortical astrocytes synthesize melatonin: absence of a diurnal rhythm. J Pineal Res. 2007;43:232-238.
83. Gris P, Cheng P, Pierson J, Maixner W, Diatchenko L. Molecular assays for characterization of alternatively spliced isoforms of the u-opioid receptor (MOR). Methods Mol Biol. 2010;617:421-435.
84. Levitt ES, Purington LC, Traynor JR. Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol Pharmacol. 2011;79:461-471.
85. Connor M. Shadows across mu-Star? Constitutively active mu-opioid receptors revisited. Br J Pharmacol. 2009 Apr,156:1041-1043.
86. Chakrabarti S, Chang A, Gintzler AR. Subcellular localization of mu-opioid receptor G(s) signaling. J Pharmacol Exp Ther. 2010;333:193-200.
87. Levitt ES, Clark MJ, Jenkins PM, Martens JR, Traynor JR. Differential effect of membrane cholesterol removal on mu-and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase. J Biol Chem. 2009;284:22108-22122.
88. Soria V, Martinez-Amoros E, Escaramis G, Valero J, Perez-Egea R, Garcia C et al. Differential Association of Circadian Genes with Mood Disorders: CRY1 and NPAS2 are Associated with Unipolar Major Depression and CLOCK and VIP with Bipolar Disorder. Neuropsychopharmacol. 2010;35:1279-1289.
89. Miller CL, Murakami P, Ruczinski I, Ross RG, Sinkus M, Sullivan B, et al. Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res. 2009;113: 259-267.
90. Beaudry H, Dubois D, Gendron L. Activation of spinal mu-and delta-opioid receptors potently inhibits substance P release induced by peripheral noxious stimuli. J Neurosc. 2011;31:13068-13077.
91. Stefano GB, Kŕaĺickova M, Ptacek R, Kuzelova H, Esch T, Kream RM. Low dose morphine adjuvant therapy for enhanced efficacy of antipsychotic drug action: Potential involvement of endogenous morphine in the pathophysiology of schizophrenia. Med Sci Monit. 2012;18:HY23-26.
92. Parker KE, McCall JG, Will MJ. Basolateral amygdala opioids contribute to increased high-fat intake following intra-accumbens opioid administration, but not following 24-h food deprivation. Pharmacol Biochem Behav. 2010;97:262-266.
93. Cai Z, Ratka A. Opioid system and Alzheimer's disease. Neuromol Med. 2012;14:91-111.
94. Kraus J. Regulation of mu-opioid receptors by cytokines. Front Biosci (Schol Ed). 2009;1:164-170.
95. Kraus J, Borner C, Lendeckel U, Hollt V. Interferongamma down-regulates transcription of the muopioid receptor gene in neuronal and immune cells. J Neuroimmunol. 2006;181:13-18.
96. Prossin AR, Koch AE, Campbell PL, McInnis MG, Zalcman SS, Zubieta JK. Association of plasma interleukin-18 levels with emotion regulation and / -opioid neurotransmitter function in major depression and healthy volunteers. Biol Psychiatr. 2011;69: 808-812.
97. Palladino I, Salani F, Ciaramella A, Rubino IA, Caltagirone C, Fagioli S, et al. Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. J Neuroinflam. 2012;9:206.
98. Sutinen EM, Pirttila T, Anderson G, Antero Salminen A, Ojala JO. Pro-inflammatory interleukin-18 increases Alzheimer's disease associated amyloid-B production in human neuron-like cells. J Neuroinflam. 2012;9:199.
99. Franchi S, Moretti S, Castelli M, Lattuada D, Scavullo C, Panerai AE, et al. Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages. Br Behav Immun. 2012;26:480-488.
100. Vucetic Z, Kimmel J, Totoki K, Hollenbeck E, Reyes TM. Maternal high-fat diet alters methylation and gene expression of dopamine and opioid-related genes. Endocrinol. 2010 Oct;151:4756-4764.
101. Hamer M, Batty GD, Kivimaki M. Risk of future depression in people who are obese but metabolically healthy: the English longitudinal study of ageing. Mol Psychiatr. 2012;17:940-945.
102. Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH. Neuroprotective Peffects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem. 2009;108:1116-1125.
103. Kovacs J, Pakaski M, Juhasz A, Feher A, Drotos G, Fazekas CO, et al. Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer's disease: friend or foe? Neuropsychopharmacol Hung. 2012;14:19-27.
104. Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav. 2012;101:564-574.
105. Zaidel L, Allen G, Cullum CM, Briggs RW, Hynan LS, Weiner MF, et al. Donepezil Effects on Hippocampal and Prefrontal Functional Connectivity in Alzheimer's Disease: Preliminary Report. J Alzheimers Dis. 2012;31 Suppl 3:S221-S226.
106. Jiḿenez-Palomares M, Ramos-Rodŕiguez JJ, Ĺopez-Acosta JF, Pacheco-Herrero M, Lechuga-Sancho AM, Perdomo G, et al. Increased A± production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab. 2012;302:E1373-E1380.
107. Nelson LE, Valentine RJ, Cacicedo JM, Gauthier MS, Ido Y, Ruderman NB. A novel inverse relationship between metformin-triggered AMPKSIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol. 2012;303:C4-C13.
108. Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71:377-382.
109. Johnston JM, Greco SJ, Hamzelou A, Ashford JW, Tezapsidis N. Repositioning leptin as a therapy for Alzheimer's disease. Therapy. 2011;8:481-490.
110. Julien C, Tremblay C, Emond V, Lebbadi M, Salem NJr, Bennet DA, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol. 2009;68:48-58.
111. Kishi T, Fukuo Y, Kitajima T, Okochi T,Yamanouchi Y, Kinoshita Y, et al. SIRT1 gene, schizophrenia and bipolar disorder in the Japanese population: an association study. Genes Br Beh. 2011;10:257-263.
112. Anderson G, Maes M. Melatonin: an Overlooked Factor in Schizophrenia and in the Inhibition of Anti-Psychotic Side Effects. Metab Br Dis. 2012;27: 113-119.
113. Cristofol R, Porquet D, Corpas R, Coto-Montes A, Serret J, Camins A, et al. Neurons from senescenceaccelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. J Pineal Res. 2012;52:271-281.
114. Wathen AB,West ES, Lydic R, Baghdoyan HA Olanzapine causes a leptin-dependent increase in acetylcholine release in mouse prefrontal cortex. Sleep. 2012;35:315-323.
115. Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacol. 2007;32:284-288.
116. Kilzieh N. 2012: Principal Investigator. ClinicalTrials. gov Identifier: NCT00512070 (conference presentation).